Translational lung cancer research最新文献

筛选
英文 中文
Risk factors behind the global lung cancer burden: a pan-database exploration. 全球肺癌负担背后的危险因素:一个泛数据库的探索。
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-131
Wenhan Cao, Zhixuan You, Zihui Wang, Zhiman Liang, Haiyang Li, Zhenglin Chang, Youpeng Chen, Guanghui Dong, Zhangkai Jason Cheng, Baoqing Sun
{"title":"Risk factors behind the global lung cancer burden: a pan-database exploration.","authors":"Wenhan Cao, Zhixuan You, Zihui Wang, Zhiman Liang, Haiyang Li, Zhenglin Chang, Youpeng Chen, Guanghui Dong, Zhangkai Jason Cheng, Baoqing Sun","doi":"10.21037/tlcr-2025-131","DOIUrl":"10.21037/tlcr-2025-131","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. Understanding its multifactorial risk factors is crucial for effective prevention strategies. While tobacco smoking remains the primary risk factor, the roles of other factors are less well understood across different global settings. This study aimed to provide a comprehensive analysis of global lung cancer trends from 1990 to 2021, examining associations between lung cancer outcomes and diverse environmental, socioeconomic, lifestyle, and dietary factors across 201 countries.</p><p><strong>Methods: </strong>We conducted a comprehensive analysis of lung cancer prevalence and mortality from 1990 to 2021 across 201 countries, utilizing data from multiple international databases, including the Global Burden of Disease Study and the World Health Organization. We assessed associations between lung cancer outcomes and various environmental, socioeconomic, lifestyle, and dietary factors using correlation analysis, generalized linear models, and canonical correlation analysis.</p><p><strong>Results: </strong>Globally, lung cancer cases increased from 1.40 million in 1990 to 3.25 million in 2021, while age-standardized prevalence remained relatively stable. Smoking showed the strongest correlation with lung cancer prevalence (r=0.753, P<0.001), with urbanization also showing a significant positive association (r=0.481, P<0.001). Ambient temperature was negatively correlated with lung cancer prevalence (r=-0.296, P<0.001). Cooking methods influenced risk: gas cooking was associated with lower lung cancer prevalence compared to biomass cooking. These findings highlight the complex interplay of factors influencing lung cancer risk globally.</p><p><strong>Conclusions: </strong>While smoking remains the predominant risk factor for lung cancer, other factors such as urbanization, ambient temperature, and cooking methods significantly influence global prevalence patterns. Our study underscores the need for comprehensive public health strategies that address environmental and lifestyle factors alongside traditional risk factors. These insights are critical for informing targeted interventions aimed at reducing the global burden of lung cancer, especially in the context of rapid urbanization and climate change.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2452-2469"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study. 经支气管射频消融治疗IA期周围性肺癌的安全性和有效性:一项回顾性队列研究。
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-486
Siyuan Hong, Lin Ye, Junxiang Chen, Fangfang Xie, Chuanjia Gu, Du Xu, George Cheng, Jiayuan Sun
{"title":"Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study.","authors":"Siyuan Hong, Lin Ye, Junxiang Chen, Fangfang Xie, Chuanjia Gu, Du Xu, George Cheng, Jiayuan Sun","doi":"10.21037/tlcr-2025-486","DOIUrl":"10.21037/tlcr-2025-486","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous radiofrequency ablation (RFA) is a commonly used treatment for inoperable early-stage lung cancer, though it carries a significant risk of complications. Transbronchial RFA has emerged as a promising alternative, but robust clinical evidence supporting its adoption remains scarce. This study aims to investigate the safety and efficacy of transbronchial RFA in treating early-stage peripheral lung cancer.</p><p><strong>Methods: </strong>This retrospective cohort study included patients with early-stage (IA) peripheral lung cancer who underwent transbronchial RFA due to inoperability or refusal of surgery from August 2020 to December 2023. All patients underwent transbronchial RFA under the guidance of X-ray or cone-beam computed tomography (CBCT). The safety endpoint included the incidence of adverse events in the month after ablation. The efficacy endpoints involved the local control progression-free survival (LPFS), as well as the factors affecting therapeutic outcomes.</p><p><strong>Results: </strong>A total of 46 patients with 51 tumors underwent 55 transbronchial RFA procedures. The mean age of patients was 67.7 years, and the mean lesion size was 16.4 mm. Adverse events and intervention-acquired adverse events were reported in 11.5% and 9.8% of participants. The local control analysis revealed 1-, 2-, and 3-year LPFS rates of 87.5%, 73.4%, and 69.8%, respectively. The efficacy predictor analysis revealed that transbronchial RFA guided by CBCT had significantly better LPFS compared to that of X-ray guidance (1- and 3-year LPFS rates: 97.2% <i>vs.</i> 55.4% and 79.3% <i>vs.</i> 36.9%, respectively).</p><p><strong>Conclusions: </strong>Transbronchial RFA for peripheral lung cancer showed a favorable safety profile. The efficacy of transbronchial RFA was also evaluated, and it was found that CBCT-guided bronchial ablation had better outcomes. Future studies will require prospective randomized controlled trials to further confirm its efficacy.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2736-2746"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study. 移植前恶性肿瘤患者肺移植后的生存结局和危险因素:一项国家队列研究
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-224
Xiaoqing Lan, Caikang Luo, Junjie He, Yining Pan, Fei Huang, Wei He, Jiaqin Zhang, Yanwei Lin, Zhiwei Wang, Chao Yang, Guilin Peng, Jiang Shi, Xin Xu
{"title":"Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study.","authors":"Xiaoqing Lan, Caikang Luo, Junjie He, Yining Pan, Fei Huang, Wei He, Jiaqin Zhang, Yanwei Lin, Zhiwei Wang, Chao Yang, Guilin Peng, Jiang Shi, Xin Xu","doi":"10.21037/tlcr-2025-224","DOIUrl":"10.21037/tlcr-2025-224","url":null,"abstract":"<p><strong>Background: </strong>Pre-transplant malignancy (PTM) is a relative contraindication for lung transplantation (LTx). The proportion of patients with PTM in LTx is increasing annually. We sought to identify modifiable risk factors affecting patient survival and evaluate the prognosis of different types of PTM.</p><p><strong>Methods: </strong>We retrospectively reviewed primary adult lung transplantation recipients (LTR) in the United Network for Organ Sharing (UNOS) registry. Primary stratification was performed by PTM and secondary stratification by tumor type. Kaplan-Meier survival analysis was used to estimate survival and Cox proportional hazards model was used to assess risk factors.</p><p><strong>Results: </strong>Compared to patients without PTM, patients with PTM exhibit a significantly higher mortality rate starting 1 year post-transplantation (1-year: P=0.02; 3-, 5-, 10-year: P<0.001). Multivariate Cox regression analysis identified age, male sex, single LTx, and high lung allocation score (LAS) as independent risk factors for 5-year mortality in PTM patients. After stratifying PTM, lung PTM was an independent risk factor for death at all periods after transplantation (1-year: P<0.001; 3-year: P=0.001; 5-year: P=0.002; 10-year: P=0.005), and leukemia PTM significantly impacted medium- and long-term mortality (3-year: P=0.03; 5-year: P=0.01; 10-year: P=0.004). Additionally, cutaneous melanoma and genitourinary PTM were associated with long-term mortality. Skin cancer, lung cancer and leukemia were significantly associated with cancer-specific mortality (P<0.05).</p><p><strong>Conclusions: </strong>The prognosis of patients with PTM after LTx is worse than that of patients without PTM. When focusing on long-term survival, patients with a history of lung cancer, leukemia, melanoma and genitourinary system malignant tumors require more careful selection.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2598-2610"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KRAS and STK11 co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response. KRAS和STK11共突变在可切除的非小细胞肺癌中:持久的预后价值和受损的免疫治疗反应
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-22 DOI: 10.21037/tlcr-2025-463
Luisana Sisca, Priscilla Cascetta, Ayesha Aijaz, Chiara Catania, Francesco Facchinetti, Abdul Rafeh Naqash, Biagio Ricciuti, Alessio Cortellini
{"title":"<i>KRAS</i> and <i>STK11</i> co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response.","authors":"Luisana Sisca, Priscilla Cascetta, Ayesha Aijaz, Chiara Catania, Francesco Facchinetti, Abdul Rafeh Naqash, Biagio Ricciuti, Alessio Cortellini","doi":"10.21037/tlcr-2025-463","DOIUrl":"10.21037/tlcr-2025-463","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2374-2382"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arachidonic acid-mediated autophagy regulation drives crizotinib resistance in lung cancer: therapeutic opportunities and challenges. 花生四烯酸介导的自噬调节驱动肺癌克里唑替尼耐药:治疗的机遇和挑战。
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-615
Hui Jie, Hongjin Lai, Zihuai Wang, Lunxu Liu, Senyi Deng, Chenglin Guo
{"title":"Arachidonic acid-mediated autophagy regulation drives crizotinib resistance in lung cancer: therapeutic opportunities and challenges.","authors":"Hui Jie, Hongjin Lai, Zihuai Wang, Lunxu Liu, Senyi Deng, Chenglin Guo","doi":"10.21037/tlcr-2025-615","DOIUrl":"10.21037/tlcr-2025-615","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2893-2894"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells. 芬苯达唑和二氯乙酸二异丙胺对A549肺癌细胞移植免疫缺陷BALB/c裸鼠的协同抗肿瘤作用。
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-25 DOI: 10.21037/tlcr-2024-1272
Thai Q Nguyen, Uyen T T Phan, Mao V Can, Dang H Nguyen, Bo Han, Ba X Hoang
{"title":"Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells.","authors":"Thai Q Nguyen, Uyen T T Phan, Mao V Can, Dang H Nguyen, Bo Han, Ba X Hoang","doi":"10.21037/tlcr-2024-1272","DOIUrl":"10.21037/tlcr-2024-1272","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Recent studies suggest that fenbendazole (FZ), even at micromolar doses, shows promising anticancer potential but can cause liver toxicity in some patients. Diisopropylamine dichloroacetate or vitamin B15 (DADA), known for its hepatoprotective properties, has also demonstrated antitumor properties and may reduce FZ-induced liver injury. Our research aimed to evaluate the synergistic anticancer effects of FZ and DADA <i>in vivo</i> lung cancer models.</p><p><strong>Methods: </strong>Immunodeficient BALB/c nude mice (Foxn1nu) were utilized for <i>in vivo</i> assessment of anticancer activity. Human lung cancer cells (A549) were injected into the nude mice. When the tumor volume reached 50 mm<sup>3</sup>, the animals were randomized into eight groups, receiving either single or combined DADA and FZ treatments. The antitumor efficacy and toxicity were monitored over a 60-day period.</p><p><strong>Results: </strong>DADA and FZ improved the safety profiles in BALB/c nude mice. In the animal model, combined treatment with 100 mg/kg DADA and 40 mg/kg FZ resulted in a 50% reduction in complete tumor regression, compared to 11.1% and 0% in the single-agent treatment groups, respectively. The combination therapy showed superior efficacy in reducing tumor size and inducing tumor loss compared to either treatment alone.</p><p><strong>Conclusions: </strong>Combining oral treatment of 100 mg/kg DADA and 40 mg/kg FZ synergistically inhibited tumor growth in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells. A clinical study is warranted to prove the efficacy and safety of this well-characterized drug combination as a repurposing treatment for lung cancer.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2509-2521"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer. 非小细胞肺癌围手术期免疫检查点抑制剂免疫生物标志物的机制研究
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-16 DOI: 10.21037/tlcr-2025-162
Yanting Long, Runsen Jin, Hecheng Li
{"title":"Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer.","authors":"Yanting Long, Runsen Jin, Hecheng Li","doi":"10.21037/tlcr-2025-162","DOIUrl":"10.21037/tlcr-2025-162","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis have revolutionized the treatment of non-small cell lung cancer (NSCLC), demonstrating remarkable efficacy in advanced-stage patients. These therapies have demonstrated durable responses and improved survival outcomes. Recently, perioperative ICIs have emerged as a promising approach for early-stage resectable NSCLC to address high postoperative recurrence rates and improve long-term survival. Clinical trials on adjuvant, neoadjuvant, and a combination of both perioperative ICIs therapies, such as CheckMate 816 and KEYNOTE-671, have demonstrated improvements in pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). However, challenges remain, including low response rates in NSCLC patients and the occurrence of immune-related adverse events (irAEs). These factors highlight the urgent need for robust predictive biomarkers to better stratify patients and guide clinical decision-making. While numerous studies have explored the predictive and guiding value of various biomarkers, few have reached clinical application, leaving significant gaps. Moreover, the complexity and heterogeneity of tumor-immune interactions underscore the need for integrated, multimodal predictive models. This review highlights the current state and unresolved challenges in perioperative ICIs treatment for early-stage resectable NSCLC, emphasizing the critical role of biomarkers in advancing these therapies. It provides a comprehensive summary of potential biomarkers identified in recent research, elucidating their predictive mechanisms and interrelationships. The goal is to inspire the discovery of novel biomarkers and support the integration of multiple biomarkers for combined predictive models, ultimately optimizing patient selection and therapeutic outcomes.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2821-2841"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimally invasive vs. open chest wall resection in non-small cell lung cancer: a systematic review and meta-analysis. 微创与开放式胸壁切除术治疗非小细胞肺癌:一项系统综述和荟萃分析。
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-358
Paula Duarte D'Ambrosio, Rachid Eduardo Noleto da Nobrega Oliveira, Marcelo Albuquerque Barbosa Martins, Isabella Cabianca Moriguchi Caetano Salvador, Luiza Gonzalez de Andrade, Ricardo Mingarini Terra, Paulo Manuel Pêgo-Fernandes, José Ribas Milanez Campos
{"title":"Minimally invasive <i>vs</i>. open chest wall resection in non-small cell lung cancer: a systematic review and meta-analysis.","authors":"Paula Duarte D'Ambrosio, Rachid Eduardo Noleto da Nobrega Oliveira, Marcelo Albuquerque Barbosa Martins, Isabella Cabianca Moriguchi Caetano Salvador, Luiza Gonzalez de Andrade, Ricardo Mingarini Terra, Paulo Manuel Pêgo-Fernandes, José Ribas Milanez Campos","doi":"10.21037/tlcr-2025-358","DOIUrl":"10.21037/tlcr-2025-358","url":null,"abstract":"<p><strong>Background: </strong>Minimally invasive chest wall resection (MICWR) has emerged as an alternative to open chest wall resection (OCWR) for lung cancer. This meta-analysis aims to compare perioperative outcomes between MICWR and OCWR in order to evaluate the safety and feasibility of the minimally invasive approach.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and Cochrane Library was conducted until January 20, 2025, for studies comparing MICWR and OCWR in adult patients with non-small cell lung cancer (NSCLC). The effect measures included odds ratios (ORs) for binary outcomes and mean differences (MDs) for continuous outcomes. Statistical analysis was performed using random-effects models. Heterogeneity was assessed with I<sup>2</sup> statistics.</p><p><strong>Results: </strong>Three retrospective studies comprising 2,973 patients were included, with 26.3% undergoing MICWR and 73.7% undergoing OCWR. No significant differences were found in overall mortality [OR 1.12; 95% confidence interval (CI): 0.95 to 1.32; P=0.17; I<sup>2</sup>=0%] or 90-day mortality (OR 1.00; 95% CI: 0.74 to 1.34; P=0.98; I<sup>2</sup>=0%). MICWR significantly reduced overall complications (OR 0.36; 95% CI: 0.14 to 0.93; P=0.04; I<sup>2</sup>=0%). While primary analysis showed no significant difference in length of stay (LOS) (MD -4.92 days; 95% CI: -10.36 to 0.52; P=0.08; I<sup>2</sup>=84%), sensitivity analysis (leave-one-out) eliminated heterogeneity (I<sup>2</sup>=0%) and showed a significant LOS reduction favoring MICWR (MD -7.62 days; 95% CI: -11.34 to -3.90).</p><p><strong>Conclusions: </strong>MICWR offers comparable oncologic outcomes to OCWR while reducing postoperative complications. It may also shorten LOS in selected patients. However, evidence is limited to retrospective studies, warranting prospective trials to confirm these findings and define optimal criteria.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2626-2635"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study. 化疗-免疫治疗对转移性肺腺癌患者TTF-1生物标志物阴性预后的影响:一项回顾性队列研究
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-18 DOI: 10.21037/tlcr-2025-65
Luis Posado-Domínguez, Alejandro Olivares-Hernández, Daniel Morchón-Araujo, Luis Figuero-Perez, Lorena Bellido-Hernández, Laura Corvo-Felix, Jonnathan Roldan-Ruiz, Iñigo San Miguel, Emilio Fonseca-Sanchez, Edel Del Barco-Morillo
{"title":"Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.","authors":"Luis Posado-Domínguez, Alejandro Olivares-Hernández, Daniel Morchón-Araujo, Luis Figuero-Perez, Lorena Bellido-Hernández, Laura Corvo-Felix, Jonnathan Roldan-Ruiz, Iñigo San Miguel, Emilio Fonseca-Sanchez, Edel Del Barco-Morillo","doi":"10.21037/tlcr-2025-65","DOIUrl":"10.21037/tlcr-2025-65","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of TTF-1 expression in advanced lung adenocarcinoma may be an important factor in optimizing treatment strategies. This study aimed to evaluate the impact of TTF-1 negativity on overall survival (OS) and progression-free survival (PFS) in stage IV lung adenocarcinoma patients with low PD-L1 expression treated with platinum-pemetrexed-pembrolizumab.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 155 patients with stage IV lung adenocarcinoma and PD-L1 expression <50%. We stratified patients according to TTF-1 expression. The primary survival analysis focused on 64 patients who received first-line platinum-pemetrexed chemotherapy in combination with pembrolizumab. We evaluated OS and PFS using Kaplan-Meier curves and multivariate Cox regression.</p><p><strong>Results: </strong>Among patients treated with platinum-pemetrexed-pembrolizumab, TTF-1-negative patients showed significantly shorter OS and numerically shorter PFS compared to TTF-1-positive patients. Median OS was 13 months for TTF-1-negative patients and 21 months for TTF-1-positive patients (P=0.01). Median PFS was 10 <i>vs.</i> 13 months, respectively (P=0.11). In the overall cohort, TTF-1 negativity was independently associated with a 2.3-fold increased risk of mortality (hazard ratio =2.288, 95% confidence interval: 1.073-4.879, P=0.03).</p><p><strong>Conclusions: </strong>TTF-1 negativity is an independent adverse prognostic factor in patients with stage IV lung adenocarcinoma and low PD-L1 expression. The observed differences in survival suggest that platinum-pemetrexed-pembrolizumab may be less effective for TTF-1-negative patients, and that alternative strategies should be explored in this high-risk subgroup.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2494-2508"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impacts of skip metastasis in N2a and N2b subgroups of non-small cell lung cancer: insights from a large cohort. 非小细胞肺癌N2a和N2b亚组跳跃转移对预后的影响:来自大型队列的见解
IF 3.5 2区 医学
Translational lung cancer research Pub Date : 2025-07-31 Epub Date: 2025-07-28 DOI: 10.21037/tlcr-2025-272
Shenhua Liang, Yitao Yang, Jiayuan Tian, Xingyu Luo, Zhesheng Wen, Guowei Ma
{"title":"Prognostic impacts of skip metastasis in N2a and N2b subgroups of non-small cell lung cancer: insights from a large cohort.","authors":"Shenhua Liang, Yitao Yang, Jiayuan Tian, Xingyu Luo, Zhesheng Wen, Guowei Ma","doi":"10.21037/tlcr-2025-272","DOIUrl":"10.21037/tlcr-2025-272","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of skip metastasis remains controversial in the context of the recently revised N2a (single-station) and N2b (multi-station) of non-small cell lung cancer (NSCLC). This study aims to investigate the survival impact of skip metastasis in these subgroups.</p><p><strong>Methods: </strong>We retrospectively analyzed 1,873 NSCLC patients who underwent surgery with systematic lymph node dissection at a single institution. Patients were categorized into pN1, skip pN2a, non-skip pN2a, skip pN2b, and non-skip pN2b groups. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier analysis and Cox proportional hazards regression, with propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) applied to minimize confounding.</p><p><strong>Results: </strong>Skip metastasis was identified in 34.1% of pN2 cases, with a higher incidence in pN2a (41.3%) than in pN2b (24.3%). Skip pN2a showed significantly better 5-year OS and DFS rates compared to non-skip pN2a (72% <i>vs.</i> 67%, P=0.02; 57% <i>vs.</i> 48%, P=0.002). Similarly, skip pN2b had superior outcomes compared to non-skip pN2b (5-year OS: 65% <i>vs.</i> 58%, P=0.008; DFS: 42% <i>vs.</i> 37%, P=0.03). Notably, no significant survival difference was observed between skip pN2a and pN1, or between non-skip pN2a and skip pN2b, even after PSM and IPTW adjustments.</p><p><strong>Conclusions: </strong>Skip metastasis confers a survival advantage in both pN2a and pN2b NSCLC subgroups with comparable survival between skip pN2a and pN1, as well as between non-skip pN2a and skip pN2b.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 7","pages":"2537-2559"},"PeriodicalIF":3.5,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信